73/100
✓ Peer-reviewed
alzhub usefulness score 73 out of 100.
·
JAMA
·
2017-06-01
Among the 445 participants (243 with normal amyloid, 202 with elevated amyloid), mean (SD) age was 74.0 (5.9) years, mean education was 16.4 (2.7) years, and 52% were women. 2 key findings →
Design: longitudinal study
Participants: 243
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Cerebral accumulation of amyloid-β is thought to be the starting mechanism in Alzheimer's disease. 4 key findings →
Design: longitudinal study
Participants: 437
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
For early detection of Alzheimer's disease, it is important to find biomarkers with predictive value for disease progression and clinical manifestations, such as cognitive decline. 1 key finding →
Design: longitudinal study
Participants: 282
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Despite the limited longitudinal data at the individual level and the high variability observed in such data, the study elucidates the link between the long asynchronous pathophysiological processes and the preclinical and clinical stages of AD. 2 key findings →
Design: longitudinal study
Participants: 2,014
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
The site and rate of atrophy are different across the tau-PET patterns. 1 key finding →
Design: longitudinal study
Participants: 366
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer's diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. 3 key findings →
Design: cross-sectional
Participants: 1,189
Evidence: low
Full summary, score breakdown and related studies →
Original source
For effective treatment of Alzheimer's disease (AD), it is important to identify subjects who are most likely to exhibit rapid cognitive decline. 3 key findings →
Design: longitudinal study
Participants: 139
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
We found that the association between higher baseline tau-PET levels (quantified in a temporal meta-region of interest) and rate of cognitive decline (measured with repeated Mini-Mental State Examination) was adversely modified by older age (Stβinteraction = -0.062, P = 0.032), higher education level (Stβinteraction = -0.072, P = 0.011) and higher intracranial volume (Stβinteraction = -0.07, P = 0.016). 5 key findings →
Design: cross-sectional
Participants: 200
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
These findings define a sequence of pathological events in Alzheimer's disease that support a current model of Alzheimer's disease pathogenesis in which Aβ appears early, followed by deposition of abnormal tau aggregates and subsequent neurodegeneration. 4 key findings →
Design: longitudinal study
Participants: 204
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Research utilizing magnetic resonance imaging (MRI) has been crucial to the understanding of the neuropathological mechanisms behind and clinical identification of Alzheimer's disease (AD) and mild cognitive impairment (MCI). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
NeuroImage
·
2020-07-05
While aggregation of neuroimaging datasets from multiple sites and scanners can yield increased statistical power, it also presents challenges due to systematic scanner effects. 5 key findings →
Design: cross-sectional
Participants: 663
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Amyloid deposition and neurofibrillary degeneration in Alzheimer's disease specifically affect discrete neuronal systems, but the underlying mechanisms that render some brain regions more vulnerable to Alzheimer's disease pathology than others remain largely unknown. 4 key findings →
Participants: 76
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
We analyzed data from 462 ADNI participants without dementia who underwent Aβ ([ 18 F]florbetapir or [ 18 F]florbetaben) and tau ([ 18 F]flortaucipir) PET, structural MRI, and cognitive testing. 4 key findings →
Design: cross-sectional
Participants: 156
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
57/100
✓ Peer-reviewed
alzhub usefulness score 57 out of 100.
·
PloS one
·
2012-08-02
Age is the strongest risk factor for sporadic Alzheimer disease (AD), yet the effects of age on rates of clinical decline and brain atrophy in AD have been largely unexplored. 2 key findings →
Design: longitudinal study
Participants: 723
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
A deep learning framework combining 3D CNN and LRP algorithms can be used with tau PET images to identify informative features for AD classification and may have application for early detection during prodromal stages of AD. 4 key findings →
Participants: 132
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
56/100
✓ Peer-reviewed
alzhub usefulness score 56 out of 100.
·
NeuroImage
·
2019-12-16
Alzheimer's disease (AD) is a progressive and irreversible brain degenerative disorder. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Education, occupation, premorbid intelligence, and brain size are surrogate markers for cognitive reserve. 1 key finding →
Design: longitudinal study
Participants: 819
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
We propose a novel method to identify disease-related genetic variants enriched by imaging endophenotypes, which are the imaging traits associated with both genetic factors and disease status. 5 key findings →
Design: case-control study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
β-amyloid (Aβ) pathology is not always coupled with Alzheimer's disease (AD) relevant cognitive decline. 3 key findings →
Participants: 70
Evidence: low
Full summary, score breakdown and related studies →
Original source
54/100
✓ Peer-reviewed
alzhub usefulness score 54 out of 100.
·
NeuroImage
·
2019-07-22
Individuals with Alzheimer's disease (AD) dementia exhibit significant heterogeneity across clinical symptoms, atrophy patterns, and spatial distribution of Tau deposition. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
There is both clinical and neuroanatomical variability at the single-subject level in Alzheimer's disease, complicating our understanding of brain-behaviour relationships and making it challenging to develop neuroimaging biomarkers to track disease severity, progression, and response to treatment. 5 key findings →
Participants: 1,000
Evidence: low
Full summary, score breakdown and related studies →
Original source
Tau IQ successfully calculated global tau load (Tau L ) in all 791 scans analyzed (range, -3.5% to 185.2%; mean ± SD, 23% ± 20.5%) with a nonzero additional local tau component being required in 31% of all scans (cognitively normal [CN], 22%; mild cognitive impairment [MCI], 35%; dementia, 72%). 5 key findings →
Design: cross-sectional
Participants: 615
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
53/100
✓ Peer-reviewed
alzhub usefulness score 53 out of 100.
·
PloS one
·
2017-03-06
Detecting early morphological changes in the brain and making early diagnosis are important for Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Alzheimer's disease (AD) is an irreversible brain degenerative disorder affecting people aged older than 65 years. 1 key finding →
Participants: 339
Evidence: low
Full summary, score breakdown and related studies →
Original source
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Brain
·
2017-02-15
See Vandenberghe and Schaeverbeke (doi:10.1093/awx065) for a scientific commentary on this article. 3 key findings →
Design: cross-sectional
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 33,780 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.